INTS vs JPM
Intensity Therapeutics, Inc. Common stock (INTS) versus JPMorgan Chase & Co (JPM) — a side-by-side from cached financials, not a winner call.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
JPMorgan Chase & Co (JPM) is a banks - diversified company listed on US. It is led by Jamie Dimon.
INTS does not have a complete income-statement cache yet.
Latest reported JPM revenue for 2025-12-31 was $182.45B. Net income was $57.05B. Revenue was up 2.8% from 2024-12-31 to 2025-12-31. JPM currently screens at market cap $805.69B and trailing P/E 14.2.
INTS currently screens at market cap $7.7M. JPM currently screens at market cap $805.69B and trailing P/E 14.2.
Not investment advice. Open the INTS and JPM stock pages for the full models.
Not investment advice.